

## Meaningful Use/UDS Crosswalk

### Overview:

- 44 Meaningful Use (MU) measures
- 24 UDS measures (Table 7: Health Outcomes and Disparities, and Table 6B: Quality of Care Indicators)
- 13 MU/UDS measures overlapped or shared partial data elements

### Overlaps:

#### Table 7: Health Outcomes and Disparities

- MU NQF 0059/PQRI 1 – UDS Table 7, Section C, Line 13
- MU NQF 0061/PQRI 3 – UDS Table 7, Section C, Line 9 and Section B, Line 8
- MU NQF 0055/PQRI 117 – UDS Table 7, Section C, Line 9
- MU NQF 0062/PQRI 119 – UDS Table 7, Section C, Line 9
- MU NQF 0056/PQRI 163 – UDS Table 7, Section C, Line 9
- MU NQF 0012 – UDS Table 7 – Section A, Line 1
- MU NQF 0013 – UDS Table 7, Section B, Line 8
- MU NQF 0018 – UDS Table 7, Section B, Line 8
- MU NQF 0575 – UDS Table 7, Section C, Line 12

#### Table 6B: Quality of Care Indicators

- MU NQF 0012 – UDS Table 6B, Section B (Trimester of Entry into Prenatal Care)
- MU NQF 0014 – UDS Table 6B, Section B (Trimester of Entry into Prenatal Care)
- MU NQF 0032 – UDS Table 6B, Section D (Pap Tests)
- MU NQF 0038 – UDS Table 6B, Section C (Childhood Immunizations)

### Primary differences:

- UDS uses numbers of patients while MU uses percentages.
- UDS Table 7 reports health outcomes by Race and Hispanic/Latino identity, MU does not.
- UDS Table 7 focuses on Delivery/Birth Weight, Hypertension and Diabetes (HbA1c) data only, while MU covers a wider variety of clinical measures.
- UDS Table 6B looks more at age groups and number of patients while MU covers a wider variety of clinical measures.

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE</b>				
Diabetes: Hemoglobin A1c Poor Control ( <i>NQF 0059/PQRI 1</i> )	Percentage of patients 18 – 75 years of age with diabetes (type 1 or type 2) who had hemoglobin A1c > 9.0%		<b>YES</b> <i>Refer to UDS Table 7 Health Outcomes and Disparities (Section C, Line 13).</i>	Limited overlap with the following differences: ~ UDS includes “OR No test during year.” ~ UDS does not use percentages. ~ UDS collects by Race and Hispanic/Latino identity.
Diabetes: Low Density Lipoprotein (LDL) Management and Control ( <i>NQF 0064/PQRI 2</i> )	Percentage of patients 18 – 75 years of age with diabetes (type 1 or type 2) who had LDL-C <100 mg/dL.		<b>NO</b>	UDS does not measure LDL, only HbA1c
Diabetes: Blood Pressure Management ( <i>NQF 0061/PQRI 3</i> )	Percentage of patients 18 – 75 years of age with diabetes (type 1 or type 2) who had blood pressure <140/90 mmHg.		<b>YES</b> <i>Refer to UDS Table 7 Health Outcomes and Disparities (Section C, Line 9 and Section B, Line 8).</i>	Limited overlap with the following differences: ~ UDS collects HT/Diabetes data in separate sections ~UDS Section C, Line 9 addresses diabetes ~UDS Section B, Line 8 addresses BP ~UDS collects data by Race and Hispanic/Latino identity

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) ( <i>NQF 0081/PQRI 5</i> )	Percentage of patients aged 18 years and older with a diagnosis of heart failure and LVSD (LVEF <40%) who were prescribed ACE inhibitor or ARB therapy.		<b>NO</b>	
Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) ( <i>NQF 0070/PQRI 7</i> )	Percentage of patients aged 18 years and older with a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy.		<b>NO</b>	
Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old ( <i>NQF 0041/PQRI 110</i> )	Percentage of patients aged 50 years and older who received an influenza immunization during the flu season (September through February).	Alternate Core	<b>NO</b>	

<b>Measure Title</b>	<b>Definition/Description</b>	<b>Core/Alternate</b>	<b>Overlap Between MU/UDS</b>	<b>Notes/Explanation</b>
<b>MEANINGFUL USE (continued)</b>				
Pneumonia Vaccination Status for Older Adults ( <i>NQF 0043/PQRI 111</i> )	Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.		<b>NO</b>	
Breast Cancer Screening ( <i>NQF 0031/PQRI 112</i> )	Percentage of women 40 – 69 years of age who had a mammogram to screen for breast cancer.		<b>NO</b>	
Colorectal Cancer Screening ( <i>NQF 0034/PQRI 113</i> )	Percentage of adults 50 - 75 years of age who had appropriate screening for colorectal cancer.		<b>NO</b>	
Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD ( <i>NQF 0067/PQRI 6</i> )	Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed oral antiplatelet therapy.		<b>NO</b>	

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) ( <i>NQF 0083/PQRI 8</i> )	Percentage of patients aged 18 years and older with a diagnosis of heart failure who also have LVSD (LVEF <40%) and who were prescribed beta-blocker therapy.		<b>NO</b>	
Anti-depressant medication management: (a) Effective Acute Phase Treatment (b) Effective Continuation Phase Treatment ( <i>NQF 0105/PQRI 9</i> )	The percentage of patients 18 years of age and older who were diagnosed with a new episode of major depression, treated with antidepressant medication, and who remained on an antidepressant medication treatment.		<b>NO</b>	

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation <i>(NQF 0086/PQRI 12)</i>	Percentage of patients aged 18 years and older with a diagnosis of POAG who have been seen for at least two office visits who have an optic nerve head evaluation during one or more office visits within 12 months.		<b>NO</b>	
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy <i>(NQF 0088/PQRI 18)</i>	Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months.		<b>NO</b>	

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care (NQF 0089/PQRI 19)	Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months.		<b>NO</b>	

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Asthma Pharmacologic Therapy <i>(NQF 0047/PQRI 53)</i>	Percentage of patients aged 5 through 40 years with a diagnosis of mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment.		<b>NO</b>	
Asthma Assessment <i>(NQF 0001/PQRI 64)</i>	Percentage of patients aged 5 through 40 years with a diagnosis of asthma and who have been seen for at least 2 office visits, who were evaluated during at least one office visit within 12 months for the frequency (numeric) of daytime and nocturnal asthma symptoms.		<b>NO</b>	

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Appropriate Testing for Children with Pharyngitis ( <i>NQF 0002/PQRI 66</i> )	Percentage of children 2 – 18 years of age who were diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode.		<b>NO</b>	
Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer ( <i>NQF 0387/PQRI 71</i> )	Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period.		<b>NO</b>	

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients ( <i>NQF 0385/PQRI 72</i> )	Percentage of patients aged 18 years and older with Stage IIIA through IIIC colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period.		<b>NO</b>	
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients ( <i>NQF 0389/PQRI 102</i> )	Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer.		<b>NO</b>	

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Smoking and Tobacco Use Cessation, Medical assistance: a: Advising Smokers and Tobacco Users to Quit, b: Discussing Smoking and Tobacco Use Cessation Medications, c: Discussing Smoking and Tobacco Use Cessation Strategies <i>(NQF 0027/PQRI 115)</i>	Percentage of patients 18 years of age and older who were current smokers or tobacco users, who were seen by a practitioner during the measurement year and who received advice to quit smoking or tobacco use or whose practitioner recommended or discussed smoking or tobacco use cessation medications, methods or strategies.		<b>NO</b>	

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Diabetes Eye Exam ( <i>NQF 0055/PQRI 117</i> )	Percentage of patients 18 – 75 years of age with diabetes (type 1 or type 2) who had a retinal or dilated eye exam or a negative retinal exam (no evidence of retinopathy) by an eye care professional.		<b>YES</b> <i>Refer to UDS Table 7 Health Outcomes and Disparities (Section C, Line 9).</i>	Partial overlap with the following differences: ~ Similar UDS measure only collects number of patients 18 – 75 w/type 1 or 2 diabetes ~UDS collects data by Race and Hispanic/Latino identity
Diabetes: Urine Screening ( <i>NQF 0062/PQRI 119</i> )	Percentage of patients 18 – 75 years of age with diabetes (type 1 or type 2) who had a nephropathy screening test or evidence of nephropathy.		<b>YES</b> <i>Refer to UDS Table 7 Health Outcomes and Disparities (Section C, Line 9).</i>	Partial overlap with the following differences: ~ Similar UDS measure only collects number of patients 18 – 75 w/type 1 or 2 diabetes ~UDS collects data by Race and Hispanic/Latino identity
Adult Weight Screening and Follow-Up ( <i>NQF 0421/PQRI 128</i> )	Percentage of patients aged 18 years and older with a calculated BMI in the past six months or during the current visit documented in the medical record AND if the most recent BMI is outside parameters, a follow-up plan is documented.	<b>CORE</b>	<b>NO</b>	

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Diabetes: Foot Exam ( <i>NQF 0056/PQRI 163</i> )	The percentage of patients aged 18 – 75 years with diabetes (type 1 or type 2) who had a foot exam (visual inspection, sensory exam with monofilament, or pulse exam).		<b>YES</b> <i>Refer to UDS Table 7 Health Outcomes and Disparities (Section C, Line 9).</i>	Partial overlap with the following differences: ~ Similar UDS measure only collects number of patients 18 – 75 w/type 1 or 2 diabetes ~UDS collects data by Race and Hispanic/Latino identity

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol ( <i>NQF 0074/PQRI 197</i> )	Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed a lipid-lowering therapy (based on current ACC/AHA guidelines).		<b>NO</b>	
Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation ( <i>NQF 0084/PQRI 200</i> )	Percentage of all patients aged 18 years and older with a diagnosis of heart failure and paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy.		<b>NO</b>	
Ischemic Vascular Disease (IVD): Blood Pressure Management ( <i>NQF 0073/PQRI 201</i> )	Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1 – November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and whose recent blood pressure is in control (<140/90 mmHg).		<b>NO</b>	

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic ( <i>NQF 0068/PQRI 204</i> )	Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1 – November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and who had documentation of use of aspirin or another antithrombotic during the measurement year.		<b>NO</b>	

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation (b) Engagement <i>(NQF 0004)</i>	The percentage of adolescent and adult patients with a new episode of alcohol and other drug (AOD) dependence who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis and who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.		<b>NO</b>	

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Prenatal Care: Screening for Human Immunodeficiency Virus (HIV) (NQF 0012)	Percentage of patients, regardless of age, who gave birth during a 12-month period who were screened for HIV infection during the first or second prenatal care visit.		<b>YES</b> <i>Refer to UDS Table 7, Section A, Line 1, and UDS Table 6B, Section A and Section B</i>	Limited overlap with the following differences re Table 7: ~UDS collects HIV and delivery/birth weight data separately ~ UDS collects data by Race and Hispanic/Latino Identity. ~UDS does not use percentages ~UDS looks at total number of HIV positive pregnant women (MU uses “screened”). Table 6: ~ UDS only collects age and entry into prenatal care.

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Hypertension: Blood Pressure Measurement ( <i>NQF 0013</i> )	Percentage of patient visits for patients aged 18 years and older with a diagnosis of hypertension who have been seen for at least 2 office visits, with blood pressure (BP) recorded.	<b>Core</b>	<b>YES</b> <i>Refer to UDS Table 7, Section B, Line 8</i>	Limited overlap with the following differences: ~ UDS collects hypertension data for ages 18 – 85 with a previous BP reading less than 140/90 ~ UDS looks at total number of patients by Race and Hispanic/Latino Identity.
Prenatal Care: Anti-D Immune Globulin ( <i>NQF 0014</i> )	Percentage of D (Rh) negative, unsensitized patients, regardless of age, who gave birth during a 12-month period who received anti-D immune globulin at 26 – 30 weeks gestation.		<b>YES</b> <i>Refer to UDS Table 6B, Section A and Section B</i>	Limited overlap with the following differences: ~ UDS only collects age and entry into prenatal care.
Controlling High Blood Pressure ( <i>NQF 0018</i> )	The percentage of patients 18 – 85 years of age who had a diagnosis of hypertension and whose BP was adequately controlled during the measurement year.		<b>YES</b> <i>Refer to UDS Table 7, Section B, Line 8</i>	Limited overlap with the following differences: ~ UDS collects percentages and BP's less than 140/90.

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Weight Assessment and Counseling for Children and Adolescents ( <i>NQF 0024</i> )	Percentage of patients 2 – 17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or OB/GYN and who had evidence of BMI percentile documentation, counseling for nutrition and counseling for physical activity during the measurement year.	<b>Alternate Core</b>	<b>NO</b>	
Preventive Care and Screening Measure Pair: a: Tobacco Use Assessment b: Tobacco Cessation Intervention ( <i>NQF 0028</i> )	Percentage of patients aged 18 years and older who have been seen for at least 2 office visits who were queried about tobacco use one or more times within 24 months b. Percentage of patients aged 18 years and older identified as tobacco users within the past 24 months and have been seen for at least 2 office visits, who received cessation intervention.	<b>Core</b>	<b>NO</b>	
Cervical Cancer Screening <i>NQF (0032)</i>	Percentage of women 21 – 64 years of age, who received one or more Pap tests to screen for cervical cancer.		<b>YES</b>	Partial overlap with the following differences: ~ UDS collects percentages and women aged 24 – 64.

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Chlamydia Screening for Women ( <i>NQF 0033</i> )	Percentage of women 15 – 24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.		<b>NO</b>	
Use of Appropriate Medications for Asthma ( <i>NQF 0036</i> )	Percentage of patients 5 – 50 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement year. Report three age stratifications (5 – 11 years, 12 – 50 years, and total).		<b>NO</b>	
Childhood Immunization Status ( <i>NQF 0038</i> )	Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); two H influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); two hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday. The measure calculates a rate for each vaccine and nine separate combination rates.	<b>Alternate Core</b>	<b>YES</b>	Partial overlap with the following differences: ~ UDS collects percentages and does not collect the types of vaccinations (just the number of children receiving them).

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Low Back Pain: Use of Imaging Studies (NQF 0052)	Percentage of patients with a primary diagnosis of low back pain who did not have an imaging study (plain x-ray, MRI, CT scan) within 28 days of diagnosis.		<b>NO</b>	
Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control (NQF 0075)	Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal angioplasty (PTCA) from January 1 – November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and who had a complete lipid profile performed during the measurement year and whose LDL-C <100 mg/dL.		<b>NO</b>	

Measure Title	Definition/Description	Core/Alternate	Overlap Between MU/UDS	Notes/Explanation
<b>MEANINGFUL USE (continued)</b>				
Diabetes: Hemoglobin A1c Control (<8.0%) ( <i>NQF 0575</i> )	The percentage of patients 18 – 75 years of age with diabetes (type 1 or type 2) who had hemoglobin A1c <8.0%.		<b>Yes</b> <i>Refer to Table 7, Section C, Line 12</i>	Limited overlap with the following differences: ~ UDS collects this data by number of patients (not percentage) ~ UDS looks at A1c's between 7 & 9, ~ UDS collects data by Race and Hispanic/Latino identity.

Measure Title	Definition/Description	Additional Clarification	Overlap Between MU/UDS	Notes
<b>UDS – TABLE 7 HEALTH OUTCOMES AND DISPARTIES</b> <b>(SECTION A: DELIVERIES AND BIRTH WEIGHT BY RACE AND HISPANIC/LATINO IDENTITY)</b>				
<i>Total number of HIV positive pregnant women (Report total only)</i>				
Section A: Deliveries and Birth Weight by Race and Hispanic/Latino Identity*	Prenatal care patients who delivered during the year. <i>Section A: Line 1</i>		<b>YES</b>	Limited overlap: MU (NQF 0012) combines HIV screening and patients giving birth in previous 12 months; MU does not collect data by race/ethnicity.
	Deliveries performed by grantee provider. <i>Section A: Line 2</i>	Total number only	<b>NO</b>	
	Live births <1500 grams <i>Section A: Line 3</i>		<b>NO</b>	
	Live births 1500 – 2499 grams <i>Section A: Line 4</i>		<b>NO</b>	
	Live births ≥2500 grams <i>Section A: Line 5</i>		<b>NO</b>	
*Asian, Native Hawaiian, Pacific Islander, Black/African American, American Indian/Alaska Native, White, More than one race, Race unreported/Refused to report.				

Measure Title	Definition/Description	Additional Clarification	Overlap Between MU/UDS	Notes
<b>UDS – TABLE 7 (HEALTH OUTCOMES AND DISPARITIES) (SECTION B: HYPERTENSION BY RACE AND HISPANIC/LATINO IDENTITY)</b>				
Section B: Hypertension by Race and Hispanic/Latino Identity* <i>Patients 18 – 85 diagnosed with hypertension whose last blood pressure was less than 140/90.</i>	Total Hypertensive Patients <i>Section B: Line 6</i>		<b>YES</b>	<i>Refer to MU (Hypertension: Blood Pressure Measurement; NQF 0013)</i> Limited overlap with the following differences: ~ MU doesn't have an age cap ~ MU doesn't have a BP reading ~ MU collects data by percentages ~ MU doesn't collect data by Race or Hispanic/Latino identity.
	Charts sampled or EHR total <i>Section B: Line 7</i>		<b>NO</b>	

Measure Title	Definition/Description	Additional Clarification	Overlap Between MU/UDS	Notes
<b>UDS – TABLE 7 (HEALTH OUTCOMES AND DISPARITIES)</b> <b>(SECTION B: HYPERTENSION BY RACE AND HISPANIC/LATINO IDENTITY)</b> <b>CONTINUED</b>				
	Patients with HTN controlled <i>Section B: Line 8</i>		<b>YES</b>	<i>Refer to Hypertension: Blood Pressure Measurement (NQF 0018)</i> Limited overlap with the following differences: ~ MU collects percentages ~ MU has no end age ~ MU doesn't collect last BP reading
*Asian, Native Hawaiian, Pacific Islander, Black/African American, American Indian/Alaska Native, White, More than one race, Race unreported/Refused to report.				

Measure Title	Definition/Description	Additional Clarification	Overlap Between MU/UDS	Notes
<b>UDS – TABLE 7 (HEALTH OUTCOMES AND DISPARITIES) (SECTION C: DIABETES BY RACE AND HISPANIC/LATINO IDENTITY)</b>				
Section C: Diabetes by Race and Hispanic/Latino Identity* <i>Patients 18 – 75 diagnosed with Type I or Type II diabetes: Most recent test results.</i>	Total patients with diabetes. Section C: Line 9		NO	
	Charts sampled or EHR total. Section C: Line 10			
	Patients with HbA1c<7% Section C: Line 11			

Measure Title	Definition/Description	Additional Clarification	Overlap Between MU/UDS	Notes
<b>UDS – TABLE 7 (SECTION C: DIABETES BY RACE AND HISPANIC/LATINO IDENTITY) continued</b>				
	Patients with 7% ≤ HbA1c ≤ 9% Section C: Line 12		<b>YES</b>	<i>Refer to MU Diabetes: Hemoglobin A1c Poor Control (NQF 575)</i> Limited overlap with the following differences: ~ MU collects <8 ~ MU looks at percentages not numbers of patients ~ MU doesn't list "most recent test" ~ MU doesn't collect Race, Hispanic/Latino identity.

Measure Title	Definition/Description	Additional Clarification	Overlap Between MU/UDS	Notes
<b>UDS – TABLE 7 (SECTION C: DIABETES BY RACE AND HISPANIC/LATINO IDENTITY) continued</b>				
	Patients with HbA1c > 9% OR No test during year Section C: Line 13		<b>YES</b>	<i>Refer to MU Diabetes: Hemoglobin A1c Poor Control (NQF 0059/PQRI 1)</i> Limited overlap with the following differences: ~MU doesn't list "most recent test" ~ MU doesn't collect Race, Hispanic/Latino identity. ~ MU looks at percentages not numbers of patients
*Asian, Native Hawaiian, Pacific Islander, Black/African American, American Indian/Alaska Native, White, More than one race, Race unreported/Refused to report.				

Measure Title and Additional Indicators	Additional Clarification		Overlap Between MU/UDS	Notes
<b>UDS – TABLE 6B (SECTION A: AGE CATEGORIES FOR PRENATAL PATIENTS)</b>				
DEMOGRAPHIC CHARACTERISTICS OF PRENATAL CARE PATIENTS			Limited overlap (differences noted at right)	<p><i>Refer to MU Prenatal Care: Screening for HIV (NQF 0012):</i>  ~MU looks at percentages not numbers of patients  ~ MU looks at the first or second prenatal visit only in relation to those who gave birth during a 12-month period, who were screened for HIV infection.</p> <p><i>Refer to MU Prenatal Care: Anti-D Immune Globulin (NQF 0014):</i>  ~MU looks at percentages not numbers of patients  ~ MU looks at prenatal care during 26-30 weeks gestation only in relation to those D (Rh) negative, unsensitized patients, regardless of age, who gave birth during a 12-month period who received anti-D immune globulin.</p>
AGE	NUMBER OF PATIENTS			
Less than 15 years				
Ages 15 – 19				
Ages 20 – 24				
Ages 25 – 44				
Ages 45 and over				
Total patients (summary of ages)				

Measure Title	Additional Indicator	Additional Indicator	Overlap Between MU/UDS	Notes
<b>UDS – TABLE 6B (SECTION B: TRIMESTER OF ENTRY INTO PRENATAL CARE)</b>				
	Women having first visit with grantee	Women having first visit with another provider		
			<i>Limited overlap. Differences noted below.</i>	
Trimester of first known visit for women receiving prenatal care during reporting year: <i>First Trimester</i>			<i>Refer to MU Prenatal Care: Screening for HIV (NQF 0012):</i> ~MU looks at percentages not numbers of patients ~ MU looks at the first or second prenatal visit only in relation to those who gave birth during a 12-month period, who were screened for HIV infection.	
Trimester of first known visit for women receiving prenatal care during reporting year: <i>Second Trimester</i>			<i>Refer to MU Prenatal Care: Anti-D Immune Globulin (NQF 0014):</i> ~MU looks at percentages not numbers of patients ~ MU looks at prenatal care during 26-30 weeks gestation only in relation to those D (Rh) negative, unsensitized patients, regardless of age, who gave birth during a 12-month period who received anti-D immune globulin.	
Trimester of first known visit for women receiving prenatal care during reporting year: <i>Third Trimester</i>				

Measure Title	Additional Indicators	Additional Indicators	Additional Indicators	Overlap Between MU/UDS	Notes
<b>UDS – TABLE 6B (SECTION C: CHILDHOOD IMMUNIZATION)</b>					
CHILDHOOD IMMUNIZATION	TOTAL NUMBER PATIENTS WITH 2 <sup>ND</sup> BIRTHDAY DURING MEASUREMENT YEAR	NUMBER CHARTS SAMPLED OR EHR TOTAL	NUMBER PATIENTS IMMUNIZED		
				<b>Yes</b>	Limited overlap (NQF 0038)
Number of children who have received vaccines who had their 2 <sup>nd</sup> birthday during measurement year (on or prior to December 31)					<i>Refer to MU Childhood Immunization Status (NQF 0038):</i> ~MU looks at percentages not numbers of patients ~MU also looks at children 2 years of age but specifically identifies certain vaccines.

Measure Title	Additional Indicators	Additional Indicators	Additional Indicators	Overlap Between MU/UDS	Notes
<b>UDS – TABLE 6B (SECTION D: PAP TESTS)</b>					
PAP TESTS	TOTAL NUMBER OF FEMALE PATIENTS 24-64 YEARS OF AGE	NUMBER CHARTS SAMPLED OR EHR TOTAL	NUMBER OF PATIENTS TESTED		
				<b>Yes</b>	
Number of female patients aged 24-64 who had at least one Pap test performed during the measurement year or during one of the two previous calendar years.					<i>Refer to MU Cervical Cancer Screening (NQF 0032):</i> ~MU looks at percentages not numbers of patients ~ MU looks at women ages 21 - 64